BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20222045)

  • 1. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
    Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
    Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
    Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus for metastatic desmoplastic small round cell tumor.
    Thijs AM; van der Graaf WT; van Herpen CM
    Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
    Piha-Paul SA; Cohen PR; Kurzrock R
    J Clin Oncol; 2011 Sep; 29(26):e727-30. PubMed ID: 21844496
    [No Abstract]   [Full Text] [Related]  

  • 13. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study.
    Tan IB; Dolivet G; Ceruse P; Vander Poorten V; Roest G; Rauschning W
    Head Neck; 2010 Dec; 32(12):1597-604. PubMed ID: 20848401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
    Trafalis DT; Alifieris C; Dalezis P; Geromichalos G; Sitaras NM
    Anticancer Drugs; 2012 Sep; 23(8):874-82. PubMed ID: 22510794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
    J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.